Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
63,623.61 -89.69 (-0.14%) CMC Crypto 200
1,381.67 +69.05 (+5.26%)
Rafael Holdings, Inc. (RFL)
| Previous close | 1.7100 |
| Open | 1.7400 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1300 |
| Day's range | 1.7100 - 1.7200 |
| 52-week range | 1.4400 - 2.5200 |
| Volume | |
| Avg. volume | 24,164 |
| Market cap | 42.285M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | 17.20 |
| EPS (TTM) | 0.1000 |
| Earnings date | 11 Jun 2024 - 17 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireRafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79% NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024. “During fiscal 2024, we will continue to focus on advancing our existing portfolio
- GlobeNewswire
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investmentsNEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. “During fiscal 2024, we will continue to focus on advancing our existing portfolio and identifying strategic investments in companies which have the pot
- Business Wire
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
GAINESVILLE, Fla., November 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023.
